Protagenic Therapeutics Files Proxy Materials

TL;DR

PROT proxy materials filed, no fee. Shareholders likely voting soon.

AI Summary

Protagenic Therapeutics, Inc. filed a Definitive Additional Materials filing (DEFA14A) on January 6, 2025. This filing is related to proxy materials and does not require a fee. The company, formerly known as Atrinsic, Inc., is incorporated in Delaware and operates in the Pharmaceutical Preparations industry.

Why It Matters

This filing indicates that Protagenic Therapeutics is proceeding with corporate actions requiring shareholder approval, as detailed in their proxy statement.

Risk Assessment

Risk Level: low — This filing is a routine proxy statement, not indicating immediate financial distress or significant operational changes.

Key Players & Entities

• Protagenic Therapeutics, Inc. (company) — Registrant
• Atrinsic, Inc. (company) — Former company name
• 0001493152-25-001068 (filing_id) — Accession Number
• 20250106 (date) — Filing Date

FAQ

Filing Documents

• formdefa14a.htm (DEFA14A) — 20KB
• 0001493152-25-001068.txt ( ) — 22KB

From the Filing

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to §240.14a-12 PROTAGENIC THERAPEUTICS, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 PROTAGENIC THERAPEUTICS, Inc. SUPPLEMENT TO PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON february 21, 2025 January 6, 2025 On January 3, 2025, Protagenic Therapeutics, Inc., filed and commenced distribution of the Notice of Annual Meeting and Proxy Statement, dated January 3, 2025 (the Proxy Statement), with respect to the 2024 Annual Meeting of Shareholders (the Annual Meeting) to be held on February 21, 2025 at 10:00 a.m. Eastern Time online via the internet at www.virtualshareholdermeeting.com/PTIX2024. References to “Protagenic,” “the Company,” “we,” and “our” refer to Protagenic Therapeutics, Inc. This proxy statement supplement (the Supplement) provides updated information. As previously disclosed in the Proxy Statement, the Board of Directors of the Company fixed the close of business on December 30, 2024 as the record date (the Record Date) for determining shareholders entitled to notice of, and to vote at, the Annual Meeting and at any adjournment(s) or postponement(s) thereof. This Supplement is being filed to correct an inadvertent error with respect to the description of the Record Date in the section titled “Notice of Virtual Annual Meeting of Stockholders” (the Notice). As stated throughout the rest of the Proxy Statement, the correct Record Date is December 30, 2024 (not January 3, 2025, as reported in the Notice). Additionally, in the Proxy Statement, the Company inadvertently reported an incorrect number of shares of the Company’s common stock outstanding as of the Record Date. The correct number of shares of common stock outstanding as of the Record Date is 7,241,443 (not 7,143,318, as reported in the Proxy Statement). The Company is providing this Supplement solely to correct the inadvertent errors of (i) the Record Date that appears in the Notice, and (ii) the number of shares of common stock outstanding as of the Record Date, which appears on pages 3 and 4 of the Proxy Statement. Effect on Voting This Supplement does not change the proposals to be acted upon at the Annual Meeting, which are described in the Proxy Statement, except as specifically supplemented by the information contained in this Supplement. Proxy cards, voting instruction cards or Internet or telephone votes submitted before the Annual Meeting will be voted with respect to all matters properly brought before the Annual Meeting as instructed on the proxy card, voting instruction card or by the Internet or telephone vote submission. If you have already submitted your proxy card or voting instruction card or otherwise voted your shares, you do not need to take any action unless you wish to change or revoke your vote. If you have not yet voted your shares, we encourage you to vote your shares as soon as possible. Information about how to vote your shares, or change or revoke your prior vote, is available in the Proxy Statement. The proxy holders identified on the proxy card will vote your shares as indicated on the proxy card or in accordance with the Internet or telephone votes.

View Full Filing

View this DEFA14A filing on SEC EDGAR